Fibrocell Science Inc

Fibrocell Science — Technical Presentation (April 2011)

16 slides from Fibrocell Science's technical presentation, Apr 7, 2011

  1. Slide 1: Results of Study IT-H-001: Placebo-Controlled Serial Skin Biopsy Study of Azficel-T

    Results of Study IT-H-001 A Placebo-Controlled Serial Skin Biopsy Study to Histologically Evaluate Tissue Response Following Treatment With Azficel-T April 5, 2011 www.FibrocellScience.com

  2. Slide 2: Safe Harbor Provision

    This presentation includes statements that are "forward-looking statements." While management has based any forward-looking statements contained in the presentation on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on

  3. Slide 3: Outline of Presentation

    Background and Regulatory Status of Azficel-THistology Study (IT-H-001) Rationale and EndpointsIT-H-001 Study SchemaSignificant IT-H-001 Results and FindingsStudy Conclusions Outline of Presentation 3

  4. Slide 4: Presentation Disclaimer

    The data in this presentation represents a high-level summary of the final results from the IT-H-001 study.Six-month data are currently being reviewed by the FDA with a PDUFA goal of June 22, 2011. Presentation Disclaimer 4

  5. Slide 5: Background of Azficel-T

    Azficel-T (Proposed trade name: LaVivTM) is an autologous cell therapy for the treatment of facial wrinkles through augmenting the local population of fibroblasts.Azficel-T is a fibroblast cell suspension prepared from the patient's own skin.The treatments are administered in a multiple dose regimen

  6. Slide 6: Current Regulatory Status

    Azficel-T (proposed trade name: LaViv (r)) is currently under review by the FDA for the proposed indication:"LAVIV(r) is an autologous regenerative cell therapy indicated for the improvement of moderate to severe facial wrinkles (such as nasolabial fold wrinkles) in adults ^ 18 years of age. Fibroce

  7. Slide 7: IT-H-001 Study Rationale

    Pivotal Phase 3 studies IT-R-005 and IT-R-006 demonstrated the safety and statistically significant efficacy (p-values < 0.0001) of azficel-T.Because azficel-T is a first-in-class biological treatment, FDA reviewers requested a qualitative and observational histology study to understand what happens

  8. Slide 8: IT-H-001 Study Endpoints

    The study formally evaluated the following:Qualitative comparison for clinically meaningful differences in the cellular morphology of the dermis, subcutis and epidermis between azficel-T treatment, sterile saline treatment, and untreated control sites.Qualitative comparison of differences in inflamm

  9. Slide 9: IT-H-001 Study Schema

    The study was blinded and placebo-controlled with a total of 29 subjects enrolled. Seven subjects received three injections, 21 received two injections and one subject received a single injection of azficel-T in either the right or left arm (and placebo in the other arm) at five week intervals.Cutan

  10. Slide 10: Study Schema

    IT-H-001 Study Schema Treatment 1 Treatment 2 Treatment 3 Biopsy 1 Biopsy 2 Evaluation by Dermatopathologists Evaluation by Dermatopathologists Complete Response to FDA Final Study Report 5 Weeks 5 Weeks 3 Months since last treatment 3 Months 10

  11. Slide 11: Efficacy Studies IT-R-005/006 and Histology Study IT-H-001

    IT-H-001 and IT-R-005/006 Treatment 1 Treatment 2 Treatment 3 Evaluation: Demonstrated statistically significant efficacy Demonstrated safety Efficacy Studies IT-R-005 and IT-R-006 Treatment 1 Treatment 2 Treatment 3 3 Month Biopsy6 Month Biopsy Histology Study IT-H-001 Evaluation: Clinical evaluati

  12. Slide 12: Study Results Endpoint 1: Cellular Morphology

    IT-H-001 Study Results Endpoint 1: Qualitative comparison for clinically meaningful differences in the cellular morphology of the skin.No abnormal morphology of fibroblasts or other cell types was reported. 12

  13. Slide 13: Study Results Endpoint 2: Inflammatory Cell Infiltrates

    IT-H-001 Study Results Endpoint 2:Qualitative comparison of differences in inflammatory cell infiltrates.Inflammatory cell infiltrates were found more frequently in azficel-T treated tissue than placebo or untreated tissue.The frequency of infiltrate decreased from the 3-month biopsy to the 6- month

  14. Slide 14: Study Results Endpoint 3: Collagen and Elastin Fibers

    IT-H-001 Study Results Endpoint 3:Qualitative comparison of differences in the structure and organization of collagen and elastin fibers.There was no noted instances of disorganized collagen or elastin fibers. 14

  15. Slide 15: Safety Findings

    IT-H-001 Safety Findings Safety data reported from this study was consistent with the adverse event profile established for azficel-T in previous clinical studies (mild, temporary injection site reactions).A single SAE of vasculitis was reported in a 67 year old which fully resolved and was deemed "

  16. Slide 16: IT-H-001 Study Conclusions

    This study addressed all prospectively defined study endpoints.At a histological level, the response to azficel-T was limited to mild to moderate localized inflammatory infiltrate that was observed less frequently at the 6-Month biopsy as compared to the 3-Month biopsy. Tissue treated with azficel-T

Fibrocell Science — Technical Presentation (April 2011) on 6ix